No Added Benefit With Pembrolizumab for Myeloma Versus Standard of Care
Pembrolizumab added to pomalidomide or lenalidomide for multiple myeloma did not improve overall survival. In addition, pembrolizumab increased the side effects shown in phase 3 trials, a disappointing result since in phase 2 trials, there were benefits from adding pembrolizumab to pomalidomide and dexamethasone. Also, median progression-free survival decreased at 6 months. Read more. 

Niraparib Monotherapy for Advanced Gynecologic Cancers
Niraparib gained FDA approval for treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is deemed to be homologous recombination deficiency–positive. This new indication is based on a phase 2 trial estimated to be completed in the next month. Read more.